 A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan fixed combination brimonidine tartrate 0.2timolol maleate 0.5 and Cosopt fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions on ocular blood flow as measured by retrobulbar blood flow. 